

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Craig Adam R			2. Issuer Name and Ticker or Trading Symbol CTI BIOPHARMA CORP [CTIC]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President and CEO		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/29/2022			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
3101 WESTERN AVENUE SUITE 800			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) SEATTLE WA 98121								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
common stock	12/29/2022		M		13,800	A	\$0.8411	41,661	D	
common stock	12/29/2022		S ⁽¹⁾		13,800	D	\$6	27,861	D	
common stock	12/30/2022		A ⁽²⁾		1,579	A	\$5.1085	29,440	D	
common stock	12/30/2022		M		12,000	A	\$0.8411	41,440	D	
common stock	12/30/2022		S ⁽¹⁾		12,000	D	\$6	29,440	D	
common stock	12/30/2022		M		700	A	\$0.8411	30,140	D	
common stock	12/30/2022		S ⁽¹⁾		700	D	\$6.005	29,440	D	
common stock	12/30/2022		M		4,400	A	\$0.8411	33,840	D	
common stock	12/30/2022		S ⁽¹⁾		4,400	D	\$6.01	29,440	D	
common stock	01/03/2023		M		84,683	A	\$0.8411	114,123	D	
common stock	01/03/2023		S ⁽¹⁾		84,683	D	\$6.0133 ⁽³⁾	29,440	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$0.8411	12/29/2022		M			13,800	(4)	05/16/2029	Common Stock	13,800	\$0	657,154	D	
Non-Qualified Stock Option (right to buy)	\$0.8411	12/30/2022		M			12,000	(4)	05/16/2029	Common Stock	12,000	\$0	645,154	D	
Non-Qualified Stock Option (right to buy)	\$0.8411	12/30/2022		M			700	(4)	05/16/2029	Common Stock	700	\$0	644,454	D	
Non-Qualified Stock Option (right to buy)	\$0.8411	12/30/2022		M			4,400	(4)	05/16/2029	Common Stock	4,400	\$0	640,054	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$0.8411	01/03/2023		M			84,683	(4)	05/16/2029	Common Stock	84,683	\$0	555,371	D	

Explanation of Responses:

- This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- Shares acquired under the CTI BioPharma Corp. 2007 Employee Stock Purchase Plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.00 to \$6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.

Adam R. Craig

01/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.